MedPath

Study of the effects of febuxostat in patients with diabetic nephropathy.

Not Applicable
Conditions
Diabetic nephropathy
Registration Number
JPRN-UMIN000015547
Lead Sponsor
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with a history of hypersensitivity to febuxostat 2)Patients with secondary hyperuricemia 3)Systolic blood pressure 160 mmHg or higher, or diastolic blood pressure 100 mmHg or more 4)AST or ALT levels are more than double of the normal range 5)Patients who have the following disease were excluded. Non- diabetic chronic kidney disease: glomerulonephritis , renal sclerosis , polycystic kidney disease , inflammatory disease or infection, malignant tumor 6)Patients who develop coronary artery disease , cerebrovascular disease within six months 7)Patients who are administered mercaptopurine hydrate (Roikerin), azathioprine (Imran Azanin) 8)Alcoholics(2 Go / day or more sake in a week average) 9)Patients in Breast-feeding or pregnancy 10)Patients judged by the investigator to be ineligible for some other reason

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath